Table I.
Characteristics of the 26 patients eligible for sorafenib treatment.
| Characteristics | Value |
|---|---|
| Gender, n (%) | |
| Male | 18 (69) |
| Female | 8 (31) |
| Median age, years (range) | 69 (58–81) |
| Underlying liver disease, n (%) | |
| HCV | 15 (58) |
| HBV | 8 (31) |
| HCV and HBV | 3 (11) |
| Child-Pugh classification, n (%) | |
| A5–6 | 20 (77) |
| B7 | 6 (23) |
| Previous treatments for HCC, n (%) | |
| No treatment | 5 (19) |
| Resection | 4 (16) |
| TACE | 5 (19) |
| PEI/RFA | 12 (46) |
HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; PEI, percutaneous ethanol injection; RFA, radiofrequency interstitial thermal ablation.